Philip W Tipton1, Takuya Konno2, Daniel F Broderick3, Dennis W Dickson4, Zbigniew K Wszolek5. 1. Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address: tipton.philip@mayo.edu. 2. Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address: konno.takuya@mayo.edu. 3. Department of Radiology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address: Broderick.daniel.f@mayo.edu. 4. Department of Neuroscience, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address: dickson.dennis@mayo.edu. 5. Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address: wszolek.zbigniew@mayo.edu.
Abstract
INTRODUCTION: The significant symptom overlap between progressive supranuclear palsy (PSP) and other parkinsonian neurodegenerative diseases frequently results in misdiagnosis. However, neuroimaging can be used to quantify disease-related morphological changes and specific markers. The cerebral peduncle angle (CPA) has been shown to differentiate clinically diagnosed PSP from other parkinsonian diseases but this result has yet to be confirmed in autopsy-proven disease. METHODS: Magnetic resonance imaging (MRI) scans were obtained for 168 patients representing 69 medical facilities. Following randomization, the images were divided into two groups (Type 1 and Type 2) based upon midbrain morphological differences. Two readers were blinded and independently measured the CPA of 146 patients with autopsy-proven progressive supranuclear palsy (PSP; n = 54), corticobasal degeneration (n = 16), multiple system atrophy (MSA; n = 11) and Lewy body disease (n = 65). RESULTS: Applying two separate measurement techniques revealed no statistically significant differences in CPA measurements among any study groups regardless of classification measurement approach. The interobserver agreement showed significant differences in measurements using the Type 2 approach. CONCLUSION: Measuring the CPA on MRI is not a reliable way of differentiating among patients with PSP, corticobasal degeneration, MSA, or Lewy body disease.
INTRODUCTION: The significant symptom overlap between progressive supranuclear palsy (PSP) and other parkinsonian neurodegenerative diseases frequently results in misdiagnosis. However, neuroimaging can be used to quantify disease-related morphological changes and specific markers. The cerebral peduncle angle (CPA) has been shown to differentiate clinically diagnosed PSP from other parkinsonian diseases but this result has yet to be confirmed in autopsy-proven disease. METHODS: Magnetic resonance imaging (MRI) scans were obtained for 168 patients representing 69 medical facilities. Following randomization, the images were divided into two groups (Type 1 and Type 2) based upon midbrain morphological differences. Two readers were blinded and independently measured the CPA of 146 patients with autopsy-proven progressive supranuclear palsy (PSP; n = 54), corticobasal degeneration (n = 16), multiple system atrophy (MSA; n = 11) and Lewy body disease (n = 65). RESULTS: Applying two separate measurement techniques revealed no statistically significant differences in CPA measurements among any study groups regardless of classification measurement approach. The interobserver agreement showed significant differences in measurements using the Type 2 approach. CONCLUSION: Measuring the CPA on MRI is not a reliable way of differentiating among patients with PSP, corticobasal degeneration, MSA, or Lewy body disease.
Authors: Anna Hussl; Philipp Mahlknecht; Christoph Scherfler; Regina Esterhammer; Michael Schocke; Werner Poewe; Klaus Seppi Journal: Mov Disord Date: 2010-10-30 Impact factor: 10.338
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Klaus Gröschel; Till-Karsten Hauser; Andreas Luft; Nicholas Patronas; Johannes Dichgans; Irene Litvan; Jörg B Schulz Journal: Neuroimage Date: 2004-02 Impact factor: 6.556
Authors: Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind Journal: Semin Neurol Date: 2017-12-05 Impact factor: 3.420
Authors: Lorenzo Ugga; Renato Cuocolo; Sirio Cocozza; Giuseppe Pontillo; Andrea Elefante; Mario Quarantelli; Caterina Vicidomini; Maria Francesca De Pandis; Giovanna De Michele; Alessandra D'Amico; Oreste de Divitiis; Arturo Brunetti Journal: Neuroradiology Date: 2020-07-24 Impact factor: 2.804